GPR65 and neoplasm: To assess the impact of inhibiting GPR65 or HMGB1 on tumor progression in an in vivo context, we subcutaneously injected U87 cells, with or without tumor-associated macrophages (TAMs), into nude mice to establish subcutaneous xenograft tumors.